Re: 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.
Hartvig
Per
P
D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000494:pharmacology; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000652:urine; D009325:Nausea / Q000139:chemically induced / Q000503:physiopathology* / Q000517:prevention & control; D058831:Serotonin 5-HT3 Receptor Antagonists; D012702:Serotonin Antagonists / Q000627:therapeutic use; D013373:Substance P / Q000187:drug effects / Q000378:metabolism; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced / Q000503:physiopathology* / Q000517:prevention & control; D014840:Vomiting, Anticipatory / Q000503:physiopathology / Q000517:prevention & control
D000932:Antiemetics; D000970:Antineoplastic Agents; D058831:Serotonin 5-HT3 Receptor Antagonists; D012702:Serotonin Antagonists; D013373:Substance P; D006897:Hydroxyindoleacetic Acid